This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Pramipexole oral modified release

Updated 2 Feb 2023 | Other dopaminergic drugs


Prolonged release tablets containing pramipexole (as pramipexole dihydrochloride monohydrate)

Drugs List

  • MIRAPEXIN 1.05mg prolonged release tablet
  • MIRAPEXIN 1.57mg prolonged release tablet
  • MIRAPEXIN 2.1mg prolonged release tablet
  • MIRAPEXIN 2.62mg prolonged release tablet
  • MIRAPEXIN 260microgram prolonged release tablet
  • MIRAPEXIN 3.15mg prolonged release tablet
  • MIRAPEXIN 520microgram prolonged release tablet
  • OPRYMEA 1.05mg prolonged release tablet
  • OPRYMEA 1.57mg prolonged release tablet
  • OPRYMEA 2.1mg prolonged release tablet
  • OPRYMEA 2.62mg prolonged release tablet
  • OPRYMEA 260microgram prolonged release tablet
  • OPRYMEA 3.15mg prolonged release tablet
  • OPRYMEA 520microgram prolonged release tablet
  • PIPEXUS 1.05mg prolonged release tablet
  • PIPEXUS 1.57mg prolonged release tablet
  • PIPEXUS 2.1mg prolonged release tablet
  • PIPEXUS 2.62mg prolonged release tablet
  • PIPEXUS 260microgram prolonged release tablet
  • PIPEXUS 3.15mg prolonged release tablet
  • PIPEXUS 520microgram prolonged release tablet
  • pramipexole (base) 1.05mg prolonged release tablet
  • pramipexole (base) 1.57mg prolonged release tablet
  • pramipexole (base) 2.1mg prolonged release tablet
  • pramipexole (base) 2.62mg prolonged release tablet
  • pramipexole (base) 260microgram prolonged release tablet
  • pramipexole (base) 3.15mg prolonged release tablet
  • pramipexole (base) 520microgram prolonged release tablet
  • Therapeutic Indications


    Parkinson's disease
    Parkinson's disease (adjunctive treatment - given with levodopa)


    Patients already taking standard release pramipexole tablets may be switched to prolonged release tablets overnight, at the same total daily dose. After switching to prolonged release, the dose may be adjusted depending on the patient's therapeutic response.


    Initial treatment

    Dose should be started at 260 micrograms base (375 micrograms of salt) per day. Increase every 5 to 7 days. Titrate dosage to achieve a maximal therapeutic effect, providing patients do not experience intolerable side effects.

    Suggested dose schedule:
    Week 1 - 260 micrograms base (375 micrograms salt) daily.
    Week 2 - 520 micrograms base (705 micrograms salt) daily.
    Week 3 - 1.05 mg base (1.5 mg salt) daily.

    If a further dose increase is necessary, increase the daily dose by 520 micrograms base (750 micrograms of salt) at weekly intervals up to a maximum dose of 3.15 mg base (4.5 mg of salt) per day.
    The incidence of somnolence is increased at doses higher than 1.05 mg base (1.5 mg of salt) per day.

    Maintenance treatment

    The individual dose should be in the range of 260 micrograms base (375 micrograms of salt) to a maximum of 3.15 mg base (4.5 mg of salt) per day.

    Doses higher than 1.05 mg base (1.5 mg of salt) per day can be useful in patients with advanced disease where a reduction of levodopa therapy is intended. It is recommended that the dose of levodopa is reduced during both dose escalation and the maintenance treatment with pramipexole, depending on reactions in individual patients.


    (See Dosage; Adults)

    Patients with Renal Impairment

    Creatinine clearance 30 to 50 ml/minute
    Initiate treatment with 260 micrograms base (375 micrograms of salt) every other day. Use with caution and assess therapeutic response and tolerability before increasing to daily dosing after one week. If a further dose increase is necessary, increase by 260 micrograms base (375 micrograms of salt) at weekly intervals up to a maximum dose of 1.57 mg base (2.25 mg of salt) per day.

    Creatinine clearance below 30 ml/minute
    Not recommended. Consider use of standard release pramipexole instead.

    If renal function declines during maintenance therapy, the recommendations above should be followed.

    Additional Dosage Information

    Treatment discontinuation

    Abrupt discontinuation of dopaminergic therapy can lead to the development of a neuroleptic malignant syndrome or dopamine agonist withdrawal syndrome. Therefore, pramipexole should be tapered off at a rate of 520 micrograms base (750 micrograms of salt) per day until the daily dose has been reduced to 520 micrograms base (750 micrograms of salt). Thereafter, the dose should be reduced by 260 micrograms base (375 micrograms of salt) per day. Dopamine agonist withdrawal syndrome may appear during tapering, a temporary dose increase to the lowest effective dose may be necessary before tapering continues.

    Missed dose

    When a dose is missed, pramipexole prolonged release tablets should be taken within 12 hours of the regularly scheduled time. After 12 hours, the missed dose should be left out and the next dose taken on the following day at the next regularly scheduled time.


    Children under 18 years
    Renal impairment - creatinine clearance below 30 ml/minute

    Precautions and Warnings

    Renal impairment - creatinine clearance 30-50ml/minute
    Severe cardiovascular disorder

    Advise patient/carer risk of dopamine dysregulation syndrome (DDS)
    Reduce dose in patients with creatinine clearance of 30-50ml/min
    Advise impaired alertness may affect ability to drive or operate machinery
    Advise patient that sudden onset sleep episodes may affect ability to drive
    If visual disturbances occur, perform ophthalmic evaluation
    Monitor blood pressure especially at the start of treatment
    Monitor ophthalmic function
    Monitor patients for impulse control disorders
    Monitor patients for mania and delirium
    Review treatment if impulse control disorders symptoms occur
    Advise patient that postural hypotension may occur
    Advise patient/carer to seek medical advice if mania &/or delirium develop
    Dopamine agonists have been associated with pathological gambling
    Patient should be made aware of possible adverse effects on mood/behaviour
    Review treatment if dystonia occurs following initiation or dose increases
    Avoid abrupt withdrawal: Dopamine agonist withdrawal syndrome may occur
    Avoid abrupt withdrawal: May cause signs of neuroleptic malignant syndrome
    Consider dose reduction/tapered withdrawal if mania &/or delirium develop
    Reduce dose or discontinue if sudden onset of sleep during daily activities
    Reduce levodopa dosage during escalation and maintenance treatment
    Advise patient to avoid alcohol during treatment
    Advise patient/carer about symptoms of impulse control disorders
    Advise patients that hallucinations can occur

    Axial dystonia following treatment initiation or dose increases has been reported in patients using pramipexole for Parkinson's disease. Whilst dystonia is a symptom of Parkinson's disease itself, symptoms have been shown to improve following dose reduction or withdrawal. As such, medication regimes should be reviewed if dystonia occurs during initiation or following dose increases.

    Pregnancy and Lactation


    Use pramipexole with extreme caution in pregnancy.

    The absence of human pregnancy experience prevents an assessment of the human risk. It is not known whether pramipexole crosses the human placenta, but the low protein binding, low molecular weight and prolonged elimination half life suggest that it will. The limited animal data available does not suggest a significant risk of teratogenicity or toxicity. Toxicity was observed in rats but this was apparently caused by mechanisms not present in human pregnancy (Briggs 2015). Until more data becomes available on the effects on the human foetus, the use of pramipexole should be avoided during pregnancy. Its use, however, does not justify the termination of pregnancy or invasive diagnostic procedures. A detailed foetal ultrasound may be considered (Schaefer 2015).

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Pramipexole is contraindicated in breastfeeding.

    As pramipexole treatment inhibits secretion of prolactin in humans it most probably will inhibit lactation. The excretion of pramipexole into breast milk has not been studied in women and so very little data is available. In rats, the concentration of drug-related radioactivity was found to be higher in breast milk than in plasma. Due to the highly limited amount of human data, its recommended pramipexole should not be used during breastfeeding. However, if its use is unavoidable, breastfeeding should be discontinued.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Behavioural disturbances
    Binge eating
    Blurred vision
    Cardiac failure
    Changes in libido
    Compulsive disorders
    Decreased appetite
    Dopamine agonist withdrawal syndrome
    Dream abnormalities
    Hypersensitivity reactions
    Inappropriate secretion of antidiuretic hormone
    Pathological gambling
    Peripheral oedema
    Postural hypotension
    Reduced visual acuity
    Sudden sleep onset episodes
    Visual disturbances
    Weight changes


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2016

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Joint Formulary Committee. British National Formulary(online) London: BMJ Group and Pharmaceutical Press Accessed on 14 December 2016.

    Martindale: The Complete Drug Reference. 38th Edition. London: Brayfield A (ed). Pharmaceutical Press; 2014.

    Summary of Product Characteristics: Mirapexin prolonged release tablets. Boehringer Ingelheim Ltd. Revised February 2020.

    Summary of Product Characteristics: Oprymea 0.26 mg prolonged release tablets. Consilient Health Ltd. Revised November 2013.
    Summary of Product Characteristics: Oprymea 0.52 mg prolonged release tablets. Consilient Health Ltd. Revised November 2013.
    Summary of Product Characteristics: Oprymea 1.05 mg prolonged release tablets. Consilient Health Ltd. Revised November 2013.
    Summary of Product Characteristics: Oprymea 1.57 mg prolonged release tablets. Consilient Health Ltd. Revised November 2013.
    Summary of Product Characteristics: Oprymea 2.1 mg prolonged release tablets. Consilient Health Ltd. Revised November 2013.
    Summary of Product Characteristics: Oprymea 2.62 mg prolonged release tablets. Consilient Health Ltd. Revised November 2013.
    Summary of Product Characteristics: Oprymea 3.15 mg prolonged release tablets. Ethypharm UK Ltd. Revised June 2016.

    Summary of Product Characteristics: Pipexus prolonged-release tablets. Consilient Health Ltd. Revised November 2013.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Pramipexole. Last revised:10 March 2015.
    Last accessed: 14 December 2016

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.